As the opioid epidemic continues to cast a long shadow over communities, its smallest victims – newborns – present one of medicine’s most heart-wrenching challenges. Every hour, dozens of infants across the country are born with neonatal abstinence syndrome (NAS), a constellation of withdrawal symptoms triggered by abrupt cessation of in-utero opioid exposure. For decades, clinicians have relied on a detailed but often criticized numeric scoring tool to guide treatment decisions. Now, a landmark comparative study published in the Journal of Perinatology provides compelling evidence that a simpler, family-centered assessment philosophy dramatically reduces the need for medication and shortens hospital stays without compromising safety.
NAS emerges when a newborn’s central nervous system, accustomed to a steady supply of opioids from the maternal bloodstream, must suddenly adapt to life without the substance. Symptoms can begin within 24 to 72 hours and range from excessive crying, tremors, and hyperactive reflexes to feeding difficulties, vomiting, diarrhea, and in severe cases, seizures. The standard approach to quantifying these symptoms has long been the Finnegan Neonatal Abstinence Scoring System, a 21-item checklist that assigns points based on observed signs. Nurses evaluate the infant every few hours, and if three consecutive scores exceed a threshold—typically a total of 8—pharmacologic intervention with morphine or methadone is initiated. While systematic, the Finnegan tool has drawn criticism for its subjective elements, high inter-rater variability, and tendency to medicalize care by separating infants from their mothers in a noisy NICU environment.
Enter the Eat, Sleep, Console (ESC) approach, which flips the script from a numeric, deficit-based model to a functional assessment. Rather than tallying points for tremors or sneezing, ESC asks three straightforward questions: Is the infant able to eat an adequate volume in a coordinated manner? Can the infant sleep for at least one hour undisturbed? And can the infant be consoled within ten minutes of crying? This framework prioritizes non-pharmacologic, mother-led interventions such as rooming-in, skin-to-skin contact, breastfeeding when possible, and a low-stimulation environment. Pharmacotherapy is reserved for those who fail to meet these functional milestones, shifting the threshold for intervention away from a predetermined number.
The new study, led by researchers Iqubal, Kocherlakota, Hussein, and colleagues, directly compared these two assessment paradigms at a large tertiary care center. They retrospectively analyzed outcomes for over 300 opioid-exposed infants born between 2019 and 2025, spanning a period during which the unit transitioned from the Finnegan scoring system to the ESC model. The team meticulously tracked the proportion of infants requiring pharmacologic treatment, the duration of hospital stay, rates of breastfeeding initiation, and the need for NICU admission. By minimizing confounding variables through a rigorous statistical matching process, they isolated the effect of the assessment method itself.
The results were striking. Under the Finnegan protocol, roughly 52% of opioid-exposed infants received morphine or methadone. After the switch to ESC, that figure plummeted to 28%. The median length of hospitalization dropped from 12 days to just 6 days, a reduction that resonated both emotionally for families and economically for healthcare systems. Infants assessed via ESC were also significantly more likely to be cared for in the postpartum ward alongside their mothers rather than being transferred to the NICU, a setting associated with increased stress, disrupted bonding, and higher costs. Crucially, there was no increase in adverse events, readmissions, or rebound symptoms after discharge, underscoring the safety of the functional approach.
Digging deeper into the physiology, the researchers noted that the ESC model may better distinguish true neurologic hyperexcitability from transient, expected autonomic signs. Many behaviors captured in the Finnegan score—such as yawning, sneezing, and mild nasal stuffiness—are common even among unexposed infants and do not necessarily indicate dangerous withdrawal. By discarding these low-predictive-value items, ESC filters out noise and allows clinicians to focus on the infant’s ability to engage in life-sustaining activities. The study also highlights the self-fulfilling prophecy of a high Finnegan score: a baby separated from its mother in a bright, noisy NICU bay predictably becomes harder to console and more difficult to feed, thereby generating higher scores that trigger medication, which in turn further disrupts feeding and sleep.
The implications extend far beyond academic debate. The findings align with a broader movement in neonatology toward neuroprotective, family-integrated care. Institutions across the United States, including several state Perinatal Quality Collaboratives, have already endorsed ESC as a best practice, but adoption has been uneven, partly due to a lack of head-to-head data of this quality. The study’s publication provides the evidentiary backbone for hospitals still hesitant to abandon the familiar numeric scale. Moreover, it underscores the need to train nursing staff not in the granular cataloging of symptoms but in the subtle art of observing an infant’s functional state and empowering mothers as the primary therapeutic agents.
Of course, the ESC model is not a panacea. Infants with polysubstance exposure, preterm birth, or concurrent medical complications may still require more intensive monitoring and pharmacotherapy. The researchers caution that ESC must be implemented with clear protocols for escalation when an infant consistently fails to meet functional criteria. They also call for long-term neurodevelopmental follow-up studies to ensure that reducing pharmacologic exposure does not inadvertently impact outcomes years down the line. Nevertheless, the study’s core message is reverberating through NICUs and pediatric grand rounds: when we trust the dyad, simplify assessment, and prioritize comfort over counting, vulnerable newborns and their families stand to gain immensely.
For frontline clinicians who have long suspected that the Finnegan tool was driving rather than curbing medication use, this comparative study offers validation. It also arrives at a time when the national conversation around opioid use disorder increasingly emphasizes harm reduction and destigmatization—a philosophy that should extend to the nursery. As one of the study’s senior authors noted, “We are not just asking whether the baby shakes; we are asking whether the baby can thrive.” That shift in perspective, now backed by robust data, may finally tip the scales in favor of a gentler, evidence-based standard for the tiniest patients in the opioid crisis.
Subject of Research: Comparison of the Finnegan Neonatal Abstinence Scoring System and the Eat, Sleep, Console approach for the assessment of neonatal abstinence syndrome.
Article Title: A comparative study of two scoring systems for the assessment of neonatal abstinence syndrome.
Article References: Iqubal, R., Kocherlakota, P., Hussein, K. et al. A comparative study of two scoring systems for the assessment of neonatal abstinence syndrome. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02788-6
Image Credits: AI Generated
DOI: 10.1038/s41372-026-02788-6
Keywords: neonatal abstinence syndrome, Finnegan scoring, Eat Sleep Console, opioid withdrawal, pharmacotherapy, non-pharmacologic care, NICU, family-integrated care
